Journal article
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Abstract
Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum …
Authors
Li H; Bullock K; Gurjao C; Braun D; Shukla SA; Bossé D; Lalani A-KA; Gopal S; Jin C; Horak C
Journal
Nature Communications, Vol. 10, No. 1,
Publisher
Springer Nature
DOI
10.1038/s41467-019-12361-9
ISSN
2041-1723